Charles Schwab Investment Management Inc. Has $45.87 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Charles Schwab Investment Management Inc. lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 730,438 shares of the company's stock after purchasing an additional 17,570 shares during the period. Charles Schwab Investment Management Inc. owned about 0.77% of Vaxcyte worth $45,872,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Xponance Inc. raised its holdings in shares of Vaxcyte by 3.0% during the fourth quarter. Xponance Inc. now owns 5,672 shares of the company's stock valued at $356,000 after acquiring an additional 163 shares during the period. Ellsworth Advisors LLC grew its position in Vaxcyte by 2.6% during the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company's stock valued at $506,000 after purchasing an additional 207 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Vaxcyte by 0.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company's stock valued at $3,211,000 after purchasing an additional 296 shares in the last quarter. Strs Ohio grew its position in Vaxcyte by 3.9% during the fourth quarter. Strs Ohio now owns 10,700 shares of the company's stock valued at $671,000 after purchasing an additional 400 shares in the last quarter. Finally, Alps Advisors Inc. grew its position in Vaxcyte by 0.6% during the third quarter. Alps Advisors Inc. now owns 69,305 shares of the company's stock valued at $3,533,000 after purchasing an additional 426 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Stock Down 1.2 %

PCVX stock traded down $0.88 during trading hours on Friday, hitting $74.57. The company's stock had a trading volume of 688,017 shares, compared to its average volume of 698,171. The company has a market capitalization of $8.11 billion, a PE ratio of -17.42 and a beta of 0.94. Vaxcyte, Inc. has a 12 month low of $44.20 and a 12 month high of $82.04. The stock has a 50 day moving average price of $65.76 and a two-hundred day moving average price of $63.61.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.28. Sell-side analysts expect that Vaxcyte, Inc. will post -3.96 earnings per share for the current year.

Analysts Set New Price Targets

PCVX has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $95.00 price objective on shares of Vaxcyte in a research report on Thursday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research report on Thursday, May 9th.

Insiders Place Their Bets

In related news, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total transaction of $928,800.00. Following the completion of the sale, the chief executive officer now directly owns 477,847 shares of the company's stock, valued at approximately $29,588,286.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $61.27, for a total transaction of $490,160.00. Following the completion of the sale, the chief financial officer now directly owns 95,679 shares of the company's stock, valued at approximately $5,862,252.33. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $61.92, for a total transaction of $928,800.00. Following the sale, the chief executive officer now directly owns 477,847 shares of the company's stock, valued at $29,588,286.24. The disclosure for this sale can be found here. Insiders sold 63,294 shares of company stock valued at $4,254,105 over the last ninety days. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.